PADLOCK THERAPEUTICS
Padlock is developing medicines targeting protein-arginine deiminases (PADs), enzymes with an important role in the generation of autoantigens, inflammation, and immune complexes in autoimmune diseases. Padlock intends to explore the full biological and therapeutic footprint of protein deimination by PADs. Padlock was founded by scientists at The Scripps Research Institute and members of the Atlas Venture Life Sciences Team. Padlock's investors include Atlas Venture, Johnson & Johnson, and MS Ventures. Padlock is a seed company operating out of the Atlas Venture office in Cambridge MA.
PADLOCK THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Life Science Therapeutics
Founded:
2014-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.padlocktherapeutics.com
Total Employee:
10001+
Status:
Active
Contact:
(978) 381-9601
Email Addresses:
[email protected]
Total Funding:
37.68 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Content Delivery Network Google Universal Analytics New Relic Google Analytics IP Anonymization Add To Any Snowplow
Similar Organizations
Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Cadent Therapeutics
Cadent Therapeutics develops novel medicines that tune and modulate brain rhythms for patients with serious neurological disease.
TeraImmune
TeraImmune is a developer of cell therapeutics created for autoimmune diseases and immune-related disorders.
Current Advisors List
Founder
Investors List
Edward Kliphuis
Edward Kliphuis investment in Series A - Padlock Therapeutics
Atlas Venture
Atlas Venture investment in Series A - Padlock Therapeutics
Index Ventures
Index Ventures investment in Series A - Padlock Therapeutics
Johnson & Johnson Development Corporation
Johnson & Johnson Development Corporation investment in Series A - Padlock Therapeutics
M Ventures
M Ventures investment in Series A - Padlock Therapeutics
Official Site Inspections
http://www.padlocktherapeutics.com
- Host name: 165.89.235.72
- IP address: 165.89.235.72
- Location: Trenton United States
- Latitude: 40.2187
- Longitude: -74.7404
- Metro Code: 504
- Timezone: America/New_York
- Postal: 08629
More informations about "Padlock Therapeutics"
Padlock Therapeutics - Crunchbase Company Profile & Funding
When was the last funding round for Padlock Therapeutics? Padlock Therapeutics closed its last funding round on Dec 18, 2014 from a Series A round. Who are Padlock Therapeutics 's …See details»
Bristol Myers Squibb - Bristol-Myers Squibb Completes Previously ...
Bristol-Myers Squibb Company (NYSE: BMY) today announced that it has completed the previously announced planned acquisition of Padlock Therapeutics, Inc. . The transaction …See details»
Padlock Therapeutics Company Profile 2024: Valuation, …
Padlock Therapeutics General Information Description. Provider and developer of novel drugs. This company is focused on discovering novel therapeutics that target protein arginine deiminases an emerging class of enzymes with roles in …See details»
Bristol-Myers Squibb to Acquire Padlock Therapeutics, Inc.
Bristol-Myers Squibb Company (NYSE:BMY) and Padlock Therapeutics, Inc. announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will …See details»
Padlock Therapeutics, Inc. Company Profile | Cambridge, MA ...
Find company research, competitor information, contact details & financial data for Padlock Therapeutics, Inc. of Cambridge, MA. Get the latest business insights from Dun & Bradstreet.See details»
Padlock Therapeutics Inc - Company Profile and News
Company profile page for Padlock Therapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»
Bristol-Myers Squibb locks on to Padlock | Drug Discovery News
Mar 22, 2016 NEW YORK & CAMBRIDGE, Mass.—A definitive agreement was signed today between Bristol-Myers Squibb Co. and Padlock Therapeutics Inc. under which Bristol-Myers …See details»
Padlock Therapeutics - Chemical & Engineering News
Nov 2, 2015 Find out what Padlock Therapeutics has been up to since it appeared on C&EN’s 2015 Top Start-ups List by clicking here. Chemical & Engineering News ISSN 0009-2347See details»
Padlock Therapeutics - Acquired by BMS - medicxiventures.com
Padlock Therapeutics - Acquired by BMS. Padlock is taking a whole new approach to treating autoimmune diseases, by developing new drugs that block the protein-arginine deiminases …See details»
Bristol-Myers Squibb Completes Previously Announced ... - BioSpace
Apr 4, 2016 NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that it has completed the previously announced planned acquisition of …See details»
Bristol-Myers Squibb acquires potential keys to treating ... - Nature
May 3, 2016 Bristol-Myers Squibb (BMS) has taken over Padlock Therapeutics in a deal worth up to US$225 million in upfront and near-term payments, and US$375 million in further …See details»
BMS buys autoimmune biotech Padlock for up to $600 million
Mar 23, 2016 Bristol-Myers Squibb is to buy US biotech Padlock Therapeutics, which aims to create treatments for serious autoimmune diseases, in a deal worth up to $600 million. BMS …See details»
Bristol-Myers to Buy Padlock, Focus on Autoimmune Diseases
Mar 24, 2016 Bristol-Myers Squibb (BMY) inks a deal to acquire privately held biotech company Padlock Therapeutics to bolster its immunoscience pipeline.See details»
Bristol-Myers bags biotech upstart Padlock in $600M autoimmune …
Mar 23, 2016 Bristol-Myers Squibb has struck a $600 million deal to buy out the biotech startup Padlock Therapeutics and its autoimmune R&D platform. | Bristol-Myers Squibb has struck a …See details»
Bristol-Myers acquires Padlock Therapeutics for $600m
Apr 3, 2016 Bristol-Myers Squibb has completed the acquisition of US-based Padlock Therapeutics in a deal valued at $600m. In March, Bristol-Myers signed a definitive agreement …See details»
BMS to Acquire Padlock Therapeutics for Up to $600M
Mar 23, 2016 Bristol-Myers Squibb (BMS) said today it will acquire Padlock Therapeutics for up to $600 million in a deal that expands the buyer’s pipeline in autoimmune diseases, including …See details»
Bristol-Myers Squibb Augments Immunoscience Pipeline with …
Mar 24, 2016 Bristol-Myers Squibb recently announced that it's acquiring Padlock Therapeutics, Inc. Bristol-Myers Squibb (BMS) recently announced that it’s acquiring Padlock Therapeutics, …See details»
Bristol-Myers Squibb locks into novel autoimmune strategy
Jun 9, 2016 Padlock Therapeutics, a startup with an innovative autoimmune R&D pipeline, recently caught the eye of big pharma Bristol-Myers Squibb (BMS), barely two years after the …See details»
Padlock Therapeutics Accelerates Pipeline Development Through …
May 28, 2015 Padlock Therapeutics announced that the company has entered into an agreement to license intellectual property and a collection of assets targeted at protein …See details»
Padlock banks $23M with a fresh approach to autoimmune disease
Dec 18, 2014 But startup Padlock Therapeutics has a novel approach it believes could cut in on the inflammatory process before things get so dire, and the biotech has $23 million in fresh …See details»